ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: PUB311

Report on STOP-ACEi Trial: Reviewing Creatinine Intraclass Correlation Coefficients

Session Information

Category: Pathology and Lab Medicine

  • 1800 Pathology and Lab Medicine

Authors

  • Spencer, Sebastian, University of Hull, Hull, England, United Kingdom
  • Desborough, Robert, Hull University Teaching Hospitals NHS Trust, Hull, England, United Kingdom
  • Mehta, Samir, University of Birmingham Clinical Trials Unit, Birmingham, England, United Kingdom
  • Bhandari, Sunil, Hull University Teaching Hospitals NHS Trust, Hull, England, United Kingdom
Background

The STOP-ACEi trial assessed whether discontinuing ACE inhibitors (ACEi) or angiotensin II receptor blockers (ARBs) slows renal decline in patients with advanced chronic kidney disease (CKD). Serum creatinine, a critical biomarker for estimating glomerular filtration rate (eGFR), was measured at local laboratories throughout the study. Inter-laboratory variation may impact outcome reliability. This secondary analysis evaluated agreement between local creatinine results and a centralised re-analysis using re-run serum samples, exploring implications for clinical trials and kidney function monitoring.

Methods

Stored serum samples were re-analysed centrally using the same assay platform at baseline, year 1, year 2, and year 3. Agreement was assessed using Bland-Altman plots, scatter plots, and Pearson’s correlation. A repeated measures mixed-effects model estimated intraclass correlation coefficients (ICCs) at the patient, centre, and measurement levels. Sensitivity analyses assessed the impact of storage duration, freeze-thaw cycles, and patient-level factors on variability.

Results

Creatinine values from the centralised and local laboratories showed strong agreement (Pearson’s r = +0.91), with minimal systematic bias on Bland-Altman analysis. Most variability arose at the patient level (ICC = 0.48; 95% CI: 0.43–0.53). Centre-level variability was low (ICC = 0.05; 95% CI: 0.02–0.11), while measurement-level variability was negligible and could not be reliably estimated. Sensitivity analysis revealed no significant effects of storage conditions or freeze-thaw cycles on measurement reliability.

Conclusion

This study confirms the reliability of local laboratory creatinine measurements, with minimal inter-laboratory variability unlikely to affect trial outcomes. Patient-level differences accounted for most observed variability.

Digital Object Identifier (DOI)